Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 2/20 | 0.42 |
| ▸ | VCP | P55072 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 4/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | KARS1 | Q15046 | 2/20 | 0.37 |
| ▸ | PRKCI | P41743 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.37 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.35 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776042 | 0.91 | FGFR4 (0.40) | FGFR4VCPF10KARS1PRKCI | |
| SCHEMBL16775866 | 0.91 | FGFR4 (0.45) | FGFR4TRPV1 | |
| SCHEMBL16775850 | 0.89 | FGFR4 (0.44) | FGFR4CSF1RMETKDR | |
| SCHEMBL16775936 | 0.88 | FGFR4 (0.43) | FGFR4CNR1 | |
| SCHEMBL16776060 | 0.88 | FGFR4 (0.43) | FGFR4VCPCNR1KARS1PRKCI | |
| SCHEMBL16776071 | 0.88 | VCP (0.39) | FGFR4VCPF10KARS1TRPV1 | |
| SCHEMBL16776194 | 0.88 | FGFR4 (0.42) | FGFR4CNR1KARS1CSF1RMET | |
| SCHEMBL16776004 | 0.87 | FGFR4 (0.42) | FGFR4F10 | |
| SCHEMBL16775857 | 0.87 | FGFR4 (0.44) | FGFR4TRPV1 | |
| SCHEMBL16775997 | 0.87 | RPS6KA2 (0.41) | F10CNR1KARS1PRKCIKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | FGFR4 1754/4885VCP 1270/4885F10 1387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.